Market Overview

UPDATE: Credit Suisse Raises PT to $185 on Biogen Idec on Tysabri Restructuring

Share:
Related BIIB
ETFs, Stocks See Dwindling Buyback Support
10 Biggest Price Target Changes For Wednesday
Biogen Holds On To Lingo, And Pivotal Data For Nanobiotix (Seeking Alpha)

Credit Suisse maintained Biogen Idec (NASDAQ: BIIB) with an Outperform rating and raised the price target from $175.00 to $185.00.

Credit Suisse said, "Central to our bullish stance on BIIB is the potential upside to the overall MS franchise based our long-standing "3 buckets/NIMO" thesis. BIIB management's recent focus on the totality of the MS franchise (e.g. FY'12 call: "potential leader in the three market segments") and the Tysabri deal puts all BIIB's MS assets under 100% of their commercial control ("speaking with one voice...competitive advantages...across all of those segments of the marketplace"). The key aspects of our "3 buckets" thesis are potential for long-term SG&A operational gearing and revenue increases of all MS drugs. In our view, over time, we could see consolidation towards one salesforce with a message that effectively states "We are THE MS company. What approach to treatment would your patient like? We have the best drug in each segment"."

Biogen Idec closed at $160.30 on Thursday.

Latest Ratings for BIIB

DateFirmActionFromTo
Aug 2016Morgan StanleyMaintainsOverweight
Aug 2016Standpoint ResearchDowngradesBuyHold
Aug 2016Raymond JamesMaintainsStrong Buy

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Price Target Analyst Ratings

 

Related Articles (BIIB)

View Comments and Join the Discussion!